Napp Pharmaceuticals

Organisation

Trials

NCT00784810
Phase 4, Completed, 247 people, 4 Nov 2008

Named in competing interests

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial
Fees or honoraria, 13 Apr 2021
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial
Fees or honoraria, 13 Apr 2021

Sources: pubmed.ncbi.nlm.nih.gov